Different affinity of nuclear factor-kappa B proteins to DNA modified by antitumor cisplatin and its clinically ineffective trans isomer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F14%3A00435173" target="_blank" >RIV/68081707:_____/14:00435173 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1111/febs.12711" target="_blank" >http://dx.doi.org/10.1111/febs.12711</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/febs.12711" target="_blank" >10.1111/febs.12711</a>

Result language

angličtina

Original language name

Different affinity of nuclear factor-kappa B proteins to DNA modified by antitumor cisplatin and its clinically ineffective trans isomer

Original language description

Nuclear factor-kappa B (NF-kB) comprises a family of protein transcription factors that have a regulatory function in numerous cellular processes and are implicated in the cancer cell response to antineoplastic drugs, including cisplatin. We characterized the effects of DNA adducts of cisplatin and ineffective transplatin on the affinity of NF-kB proteins to their consensus DNA sequence (kB site). Although the kB site-NF-B protein interaction was significantly perturbed by DNA adducts of cisplatin, transplatin adducts were markedly less effective both in cell-free media and in cellulo using a decoy strategy derivatized-approach. Moreover, NF-B inhibitor JSH-23 [4-methyl-N-1-(3-phenylpropyl)benzene-1,2-diamine] augmented cisplatin cytotoxicity in ovarian cancer cells and the data showed strong synergy with JSH-23 for cisplatin. The distinctive structural features of DNA adducts of the two platinum complexes suggest a unique role for conformational distortions induced in DNA by the adduc

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

BO - Biophysics

OECD FORD branch

—

Project

<a href="/en/project/GAP301%2F10%2F0598" target="_blank" >GAP301/10/0598: Metallodrugs based on osmium, platinum and ruthenium complexes. From mechanistic studies to novel, more efficient chemotherapy of cancer</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

FEBS Journal

ISSN

1742-464X

e-ISSN

—

Volume of the periodical

281

Issue of the periodical within the volume

5

Country of publishing house

GB - UNITED KINGDOM

Number of pages

16

Pages from-to

1393-1408

UT code for WoS article

000332083600006

EID of the result in the Scopus database

—